Data for these analyses were made available to the authors through third-party license from Optum and Truven, two commercial data providers in the US. As such, the authors cannot make these data publicly available due to data use agreement. Other researchers can access these data by purchasing a license through Optum and Truven. Inclusion criteria specified in the Methods section would allow other researchers to identify the same cohort of patients we used for these analyses. Interested individuals may see <https://www.optum.com/solutions/prod-nav/product-data.html> for more information on accessing Optum data and <https://marketscan.truvenhealth.com/marketscanportal/> for more information on accessing Truven data.

Introduction {#sec007}
============

Generic drugs are a critical component of the healthcare system, accounting for approximately 90% of all US prescriptions dispensed \[[@pmed.1002763.ref001]\]. Generic drugs contain equivalent amounts of the same active ingredient(s) as their brand-name counterparts, but usually cost far less \[[@pmed.1002763.ref002]\]. Some prior studies have demonstrated improved adherence with generic drugs compared to brand-name drugs, likely due to price \[[@pmed.1002763.ref003],[@pmed.1002763.ref004]\]. Generics are approved by regulators based on evidence of pharmaceutical equivalence and bioequivalence with the brand-name product, even though they may contain different inactive ingredients. Still, many patients and providers perceive generics to be less effective and less safe than their brand-name counterparts \[[@pmed.1002763.ref005]--[@pmed.1002763.ref011]\]. Some patients explicitly express concerns about the effectiveness of generic drugs to treat their serious illnesses \[[@pmed.1002763.ref012]\]. Negative expectations with generic products may lead patients to experience negative clinical outcomes due to a complex neurobiological phenomenon often described as the nocebo effect \[[@pmed.1002763.ref013],[@pmed.1002763.ref014]\].

Randomized controlled trials comparing clinical outcomes between generic and brand-name products are rarely conducted as they are not required by regulators for generic drug approval. In certain cases---for example, when bioequivalence is disputed---rigorous evaluation of the comparative effectiveness of generic drug products in post-approval observational studies can be useful. However, in contrast to interventional studies, these observational studies do not have the advantage of blinding participants to the treatment they receive. As a result, if outcomes are mediated through negative perceptions of generic products, a theoretical concern is that comparative investigations in which participants are aware of their treatment assignment may be biased in favor of the brand-name product \[[@pmed.1002763.ref013]\]. In a recent randomized study of patients taking a brand-name β-blocker placebo tablet, a switch to a "generic" different colored placebo tablet resulted in lower reductions in blood pressure and more adverse events compared with a group that continued receiving the brand-name placebo tablet \[[@pmed.1002763.ref015]\].

In this study comparing outcomes between generic and brand-name users across 8 drug products, we aimed to address potential bias due to negative perceptions by incorporating authorized generics (AGs) in the study design ([Fig 1](#pmed.1002763.g001){ref-type="fig"}). AGs are a special type of generic; they are identical in composition and pill appearance to the brand-name product---but are marketed by brand manufacturers (or their licensees) as generics, usually after regulatory approval of other generic versions \[[@pmed.1002763.ref016]\]. Considering AG users as a distinct exposure group, we designed 2 sets of analyses to compare outcomes between users of generics and brand-name products. In the first set of analyses, we compared outcomes between generic and AG users, with AG use as a proxy for brand-name use. These analyses were designed to address possible negative perception bias against generics under the assumption that, if such bias existed, it would impact outcomes equally in both the generic and the AG groups, since patients would not be aware of the distinction between generic and AG products and patients in both groups would believe they were taking generics. In the second set of analyses, we compared outcomes between generic users and brand-name users and between AG users and brand-name users, the latter representing a negative control. Since AGs and their corresponding brand-name products have identical active and inactive ingredients, any observed differences in the rates of clinical outcomes between users of AGs and brand products can be attributed to unmeasured confounding factors or differences in adherence patterns, which can help in interpretation of generic and brand product comparisons.

![Study concept.](pmed.1002763.g001){#pmed.1002763.g001}

Two previous studies have used AGs to account for generic perception bias in comparative evaluations of brand-name versus generic medications \[[@pmed.1002763.ref017],[@pmed.1002763.ref018]\]. The first study had a small sample size of approximately 5,000 patients, which precluded analysis by specific drug product \[[@pmed.1002763.ref017]\]. The second study used the US Food and Drug Administration (FDA) Adverse Event Reporting System to compare adverse event reporting patterns between generics and AGs \[[@pmed.1002763.ref018]\], but this data source has important limitations including substantial under-reporting and limited ability to assess whether patients used brand or generic versions of drugs \[[@pmed.1002763.ref019]\]. The objective of our study was to overcome these limitations by comparing the effectiveness of brand, generic, and AG versions of 8 different drug products in 2 population-based data sources, allowing for control of potential bias due to negative perceptions.

Methods {#sec008}
=======

This study was undertaken as a part of a Cooperative Agreement (U01) with the FDA Office of Generic Drugs. As part of the funding proposal ([S1 Text](#pmed.1002763.s005){ref-type="supplementary-material"}), we specified the study hypotheses, the pool of drugs of interest, the clinical outcomes of interest, and the analytic techniques to be used. Changes in the study methods to strengthen the study design, and for practical purposes, are detailed below. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines ([S1 STROBE](#pmed.1002763.s004){ref-type="supplementary-material"} checklist).

Data sources {#sec009}
------------

Data were derived from 2 large US-based health insurance claims databases: (1) Truven MarketScan (2003 to 2015) and (2) Optum Clinformatics Data Mart (2004 to 2013). Both sources contain de-identified data that are captured during billing of routine healthcare encounters. Individuals with employer-sponsored commercial and Medicare Advantage health insurance plans from all 50 US states and the District of Columbia are represented in these data sources. In the included study years, Truven MarketScan captured the healthcare experiences of 173 million unique individuals, and Optum Clinformatics captured 55 million unique individuals. Comprehensive longitudinal information on demographics, coded inpatient and outpatient diagnoses and procedures, and outpatient prescription dispensing is recorded for all enrollees in these databases during the time of their health insurance enrollment. We selected these data sources for their size, representativeness of the employed US population, and ability to reliably identify generic-level prescription drug dispensing through National Drug Codes (NDCs). The study was approved by the Brigham and Women's Hospital Institutional Review Board and the FDA's Research in Human Subjects Committee.

Drug products {#sec010}
-------------

We had initially proposed a list of 25 drugs with marketed AGs to be included in this analysis ([S1 Text](#pmed.1002763.s005){ref-type="supplementary-material"}). This list was modified to include 20 products based on the following criteria: (1) restriction to products for which generics entered the market after 2003, which marks the start of availability of data in our sources; (2) restriction to products for which generics and AGs entered the market concurrently (i.e., within 30 days of each other), because non-concurrently marketed generics and AGs were thought to have fundamentally different use and switching patterns, which we believed could introduce bias; and (3) inclusion of a combination product (amlodipine-benazepril capsules) to expand the scope of the study to include generics of combination products. Of these 20 products, we differentiated generics from AGs using NDCs derived from the FDA NDC directory and excluded 12 products for which \>5% of filled prescriptions in our data sources had NDCs that were not found in the NDC directory. The most likely reason for the absence of these NDCs is that the NDC directory does not maintain details on discontinued NDCs. Furthermore, the quality of recording in the NDC directory is dependent upon manufacturer submissions to the FDA, which could also introduce error or missingness. The following 8 products met our inclusion criteria: alendronate tablets, amlodipine tablets, amlodipine-benazepril capsules, calcitonin salmon nasal spray, escitalopram tablets, glipizide extended release (ER) tablets, quinapril tablets, and sertraline tablets.

Study design {#sec011}
------------

### Evaluation of comparative outcomes between generic and AG users {#sec012}

For all included drug products, we compared outcomes in 2 separate patient cohorts of AG and generic users: (1) patients who had previously been dispensed the brand-name version of the drug and then switched to either an AG or generic and (2) patients who had not been dispensed the brand-name version in the prior 6 months and initiated either an AG or generic. To identify these groups, we identified patients' first prescription for the AG or generic version of a drug after a period of 6 months of continuous health plan enrollment. This prescription date was defined as the index date, and the 6-month pre-index period was defined as the baseline period. If patients had a record of a brand-name prescription for the same drug product in the baseline period, we defined them as having switched to AG or generic from the brand-name product. If they had no record of a brand-name prescription for the same drug product in the baseline period, we defined them as AG or generic initiators. Since the AGs are identical in composition and appearance to their brand-name counterparts, the comparison of AG and generic initiators addressed the clinical question of the comparative effectiveness of the brand versus generic product among patients initiating a new treatment episode with that particular treatment, while the comparison of patients switching to AG or generic from a brand-name product addressed the clinical question of the comparative effectiveness for patients who continued on the brand-name product versus patients who switched to a generic version.

### Evaluation of comparative outcomes between generic and brand users {#sec013}

Next, we compared outcomes directly between initiators of generics and initiators of brand-name products. As a negative control comparison, we also compared outcomes between initiators of AGs and initiators of the brand products. For both comparisons, patients were required to have no recorded use of any version of the medication of interest in the 6-month continuous health plan enrollment period (baseline period) before commencing any type or formulation of the drug of interest.

Outcomes of interest and follow-up {#sec014}
----------------------------------

Clinical outcomes of interest were defined based on the approved indications for the specific drug products. For the drugs treating cardiovascular disease---amlodipine tablets, amlodipine-benazepril capsules, and quinapril tablets---the outcome of interest was a composite cardiovascular endpoint comprising hospitalization with myocardial infarction or ischemic stroke as the primary discharge diagnosis or having a coronary revascularization procedure \[[@pmed.1002763.ref020],[@pmed.1002763.ref021]\]. For alendronate tablets and calcitonin salmon nasal spray, the outcome of interest was a composite non-vertebral fracture endpoint of humerus, wrist, hip, or pelvis fracture identified using discharge diagnosis codes from hospital admission claims or a combination of diagnosis codes and surgical procedures from outpatient claims \[[@pmed.1002763.ref022]\]. As escitalopram tablets and sertraline tablets are used for a variety of psychiatric conditions, including but not limited to major depressive disorder and generalized anxiety disorder, we reasoned that an endpoint that captured deterioration of patients' mental health would be suitable for comparing the effectiveness for these drugs. While specific mental health scales are not available in administrative claims, healthcare services utilization for those with mental health diagnoses is well captured. Therefore, we selected hospitalization with a psychiatric condition as the principal discharge diagnosis code as the outcome of interest for escitalopram and sertraline. For glipizide ER tablets, the outcome was initiation of insulin during the follow-up period, with the rationale that a need for treatment intensification could serve as a proxy for poor glycemic control with current treatment \[[@pmed.1002763.ref023]\]. Table A in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"} provides specific codes used to identify these outcomes.

Follow-up for the clinical outcome of interest began on the day following the index date. Follow-up continued until the occurrence of an outcome of interest, health plan disenrollment, drug discontinuation (defined as no dispensing of the index agent for at least 1 month after the end of the most recent prescription days' supply), a switch to a different version of the drug, or the end of the study period.

Covariates {#sec015}
----------

In each comparison, we identified and accounted for a core set of variables that included patient demographics (age, sex, and geographic region), a combined comorbidity score \[[@pmed.1002763.ref024]\], calendar year, and healthcare utilization factors as markers of contact with the healthcare system and general patient health, including the number of distinct prescription medications, outpatient visits, emergency department visits, and hospitalizations during the 6-month baseline period. Additionally, for each comparison, we identified and included risk factors for the outcome of interest. For example, we adjusted for hypertension, hyperlipidemia, and diabetes diagnoses, and use of other drugs treating cardiovascular disease (e.g., angiotensin converting enzyme inhibitors and angiotensin receptor blockers) for analyses of amlodipine tablets, amlodipine-benazepril capsules, and quinapril tablets. Calendar year was not included in the brand-name versus generic or brand-name versus AG comparisons because it had an extremely strong association with the exposure to brand and only weak associations with outcomes. Including such variables in statistical models is known to increase variance and can introduce additional bias \[[@pmed.1002763.ref025]\]. To minimize the impact of confounding by secular trends in brand-name versus generic and brand-name versus AG comparisons, we restricted these 2 comparisons to 2 years before and 2 years after the loss of brand-name market exclusivity for each product. All covariates were measured in the 6-month pre-index period. For a full list of covariates used in each analysis, please refer to Tables B--I and R--Y in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"}.

Statistical analysis {#sec016}
--------------------

Propensity score (PS)--based methods were used for confounding adjustment. PSs were calculated separately within each database and for each comparison as the predicted probability of being in the exposure group of interest (AGs in the AG versus generic and AG versus brand comparisons, and generics in the generic versus brand comparison) in logistic regression models conditional on the covariates described in Tables B--I and R--Y in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"} for each individual product \[[@pmed.1002763.ref026]\]. One-to-one nearest-neighbor matching within a caliper of 0.025 of the PS was implemented for each comparison \[[@pmed.1002763.ref027]\]. In the matched cohorts, incidence rates for the outcomes and incidence rate differences were calculated. Cox proportional hazards models were used to estimate outcome hazard ratios (HRs) and 95% confidence intervals (CIs). All analyses were conducted for each study drug in the 2 databases separately. Database-specific estimates were pooled using an inverse variance fixed-effects approach to provide a summary effect estimate for each comparison of interest. To address the possibility of population overlap between the 2 databases, we corrected the variance of our pooled HRs assuming 5% overlap between databases. Statistical analyses were conducted with the Aetion platform, version 2.1.2.

Results {#sec017}
=======

Evaluation of comparative outcomes between generic and AG users {#sec018}
---------------------------------------------------------------

There were a total of 1,694,878 1:1 PS-matched pairs in the comparisons of generic and AG initiators and 569,896 1:1 PS-matched pairs in the comparisons of patients switching from brand-name to generic versus AG across the 8 drug products and 2 databases, with cohort entry dates ranging between 2003 and 2015. [Table 1](#pmed.1002763.t001){ref-type="table"} summarizes the patient demographics and baseline diagnoses of the primary indications for all matched pairs for each drug product. The average age of patients included in the analysis varied substantially across drug products, with older age ranges observed for osteoporosis drugs (alendronate, 60--67 years; calcitonin salmon, 59--70 years) and cardiovascular drugs (amlodipine, 55--63 years; amlodipine-benazepril, 53--58 years; quinapril, 53--60 years) and younger age ranges seen for users of antidepressants (escitalopram, 39--50 years; sertraline 38--50 years). All patient characteristics were balanced between 1:1 PS-matched samples in each database. The distributions of patient characteristics for generic and AG users, including co-morbid conditions and co-medications, prior to PS matching are provided in Tables B--I in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"}, and after PS matching are provided in Tables J--Q in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"}.

10.1371/journal.pmed.1002763.t001

###### Characteristics of patients included in the evaluation of comparative outcomes for patients initiating authorized generics (AGs) versus generics and patients switching from brand-name to AGs versus generics after 1:1 propensity score matching in each database.

![](pmed.1002763.t001){#pmed.1002763.t001g}

  Characteristic               Optum            MarketScan                                                                                              
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ----------------- ----------------- ---------------- ----------------
  **Alendronate**                                                                                                                                       
  Number of patients           2,433            2,433            6,332            6,332            11,963            11,963            29,985           29,985
  Age: mean (SD)               60 (10)          61 (10)          62 (10)          62 (9)           63 (12)           63 (12)           67 (12)          67 (12)
  Male sex: *n* (%)            217 (8.9%)       190 (7.8%)       508 (8.0%)       530 (8.4%)       1,233 (10.3%)     1,216 (10.2%)     2,540 (8.5%)     2,390 (8.0%)
  Osteoporosis: *n* (%)        976 (40.1%)      959 (39.4%)      1,638 (25.9%)    1,640 (25.9%)    3,469 (29.0%)     3,347 (28.0%)     4,264 (14.2%)    4,202 (14.0%)
  **Amlodipine**                                                                                                                                        
  Number of patients           73,853           73,853           35,004           35,004           461,045           461,045           116,521          116,521
  Age: mean (SD)               55 (12)          55 (12)          58 (11)          58 (11)          60 (14)           60 (14)           63 (13)          63 (13)
  Male sex: *n* (%)            41,374 (56.0%)   41,591 (56.3%)   18,954 (54.1%)   18,987 (54.2%)   231,251 (50.2%)   231,779 (50.3%)   56,127 (48.2%)   56,315 (48.3%)
  Hypertension: *n* (%)        54,318 (73.5%)   53,875 (72.9%)   25,023 (71.5%)   25,083 (71.7%)   294,395 (63.9%)   293,231 (63.6%)   61,749 (53.0%)   61,963 (53.2%)
  **Amlodipine-benazepril**                                                                                                                             
  Number of patients           10,941           10,941           6,034            6,034            47,375            47,375            29,652           29,652
  Age: mean (SD)               53 (11)          53 (12)          55 (10)          55 (10)          55 (12)           54 (12)           58 (12)          58 (12)
  Male sex: *n* (%)            6,537 (59.7%)    6,626 (60.6%)    3,931 (65.1%)    3,926 (65.1%)    26,949 (56.9%)    27,314 (57.7%)    17,765 (59.9%)   17,878 (60.3%)
  Hypertension: *n* (%)        7,648 (69.9%)    7,442 (68.0%)    4,205 (69.7%)    4,133 (68.5%)    28,929 (61.1%)    28,519 (60.2%)    16,882 (56.9%)   16,649 (56.1%)
  **Calcitonin salmon**                                                                                                                                 
  Number of patients           1,054            1,054            458              458              7,420             7,420             2,892            2,892
  Age: mean (SD)               59 (13)          59 (13)          65 (11)          65 (11)          67 (15)           67 (15)           70 (13)          70 (12)
  Male sex: *n* (%)            181 (17.2%)      191 (18.1%)      42 (9.2%)        44 (9.6%)        1,243 (16.8%)     1,265 (17.0%)     244 (8.4%)       252 (8.7%)
  Osteoporosis: *n* (%)        438 (41.6%)      443 (42.0%)      133 (29.0%)      128 (27.9%)      2,506 (33.8%)     2,493 (33.6%)     633 (21.9%)      634 (21.9%)
  **Escitalopram**                                                                                                                                      
  Number of patients           24,445           24,445           12,693           12,693           127,803           127,803           134,311          134,311
  Age: mean (SD)               39 (15)          39 (15)          46 (15)          46 (15)          43 (18)           43 (18)           50 (16)          50 (16)
  Male sex: *n* (%)            8,340 (34.1%)    8,313 (34.0%)    3,785 (29.8%)    3,830 (30.2%)    41,048 (32.1%)    40,679 (31.8%)    40,019 (29.8%)   40,095 (29.9%)
  Depression: *n* (%)          2,455 (10.0%)    2,451 (10.0%)    1,136 (8.9%)     1,185 (9.3%)     12,928 (10.1%)    12,406 (9.7%)     10,025 (7.5%)    10,222 (7.6%)
  Anxiety: *n* (%)             2,541 (10.4%)    2,544 (10.4%)    1,258 (9.9%)     1,297 (10.2%)    11,363 (8.9%)     10,827 (8.5%)     9,566 (7.1%)     9,572 (7.1%)
  **Glipizide**                                                                                                                                         
  Number of patients           2,193            2,193            723              723              66,713            66,713            2,840            2,840
  Age: mean (SD)               58 (11)          58 (12)          60 (10)          60 (11)          59 (13)           59 (13)           65 (11)          65 (12)
  Male sex: *n* (%)            1,242 (56.6%)    1,237 (56.4%)    429 (59.3%)      438 (60.6%)      37,126 (55.7%)    37,120 (55.6%)    1440 (50.7%)     1413 (49.8%)
  Diabetes mellitus: *n* (%)   1,414 (64.5%)    1,424 (64.9%)    642 (88.8%)      637 (88.1%)      52,524 (78.7%)    52,218 (78.3%)    2118 (74.6%)     2164 (76.2%)
  **Quinapril**                                                                                                                                         
  Number of patients           8,335            8,335            14,369           14,369           32,074            32,074            25,766           25,766
  Age: mean (SD)               53 (12)          53 (12)          57 (10)          57 (10)          57 (13)           57 (13)           60 (12)          60 (12)
  Male sex: *n* (%)            4,784 (57.4%)    4,787 (57.4%)    8,659 (60.3%)    8,625 (60.0%)    17,551 (54.7%)    17,642 (55.0%)    13,992 (54.3%)   14,004 (54.4%)
  Hypertension: *n* (%)        5,085 (61.0%)    5,091 (61.1%)    9,467 (65.9%)    9,452 (65.8%)    16,398 (51.1%)    16,483 (51.4%)    11,250 (43.7%)   11,303 (43.9%)
  **Sertraline**                                                                                                                                        
  Number of patients           177,959          177,959          48,019           48,019           639,270           639,270           107,155          107,155
  Age: mean (SD)               38 (15)          38 (15)          44 (14)          44 (14)          41 (17)           41 (18)           50 (17)          50 (17)
  Male sex: *n* (%)            58,874 (33.1%)   58,888 (33.1%)   13,879 (28.9%)   13,789 (28.7%)   207,094 (32.4%)   206,597 (32.3%)   30,583 (28.5%)   30,548 (28.5%)
  Depression: *n* (%)          16,977 (9.5%)    16,764 (9.4%)    3,762 (7.8%)     3,764 (7.8%)     59,015 (9.2%)     56,989 (8.9%)     5,536 (5.2%)     5,496 (5.1%)
  Anxiety: *n* (%)             15,636 (8.8%)    15,353 (8.6%)    3,280 (6.8%)     3,293 (6.9%)     47,887 (7.5%)     46,455 (7.3%)     4,134 (3.9%)     4,114 (3.8%)

Incidence rates for individual endpoints were generally consistent in all comparisons across the 2 databases ([Table 2](#pmed.1002763.t002){ref-type="table"}). The rates of psychiatric hospitalization were lower among patients switching from brand-name products to generics or AGs (range 8.7 to 15.5/1,000 person-years) compared to patients initiating generics or AGs (range 21.2 to 49.8/1,000 person-years) in both databases for escitalopram and sertraline. The initiator group had high use of other antidepressants at baseline compared to patients switching from brand-name products to generics or AGs (Tables F and I in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"}), suggesting that the initiator group likely represented patients with treatment-resistant depression while the patients switching from brand-name products to generics or AGs represented patients continued on a single antidepressant.

10.1371/journal.pmed.1002763.t002

###### Outcome incidence rates for patients initiating authorized generics (AGs) versus generics, and patients switching from brand-name products to AGs versus generics, after 1:1 propensity score matching in each database.
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  Characteristic                                 Optum                   MarketScan                                                                                           
  ---------------------------------------------- ----------------------- ------------ ----------------------- -------- --------------------- --------- ---------------------- ---------
  **Alendronate**                                                                                                                                                             
  Sample size                                    2,433                   2,433        6,332                   6,332    11,963                11,963    29,985                 29,985
  Total person-years                             626                     1,602        2,378                   6,212    3,069                 8,540     11,406                 29,819
  *n* fracture events                            11                      13           33                      65       49                    125       164                    412
  Incidence rate/1,000 py                        17.57                   8.11         13.88                   10.46    15.97                 14.64     14.38                  13.82
  Incidence rate difference (95% CI)             9.46 (−1.82, 20.74)     Ref          3.42 (−1.96, 8.79)      Ref      1.33 (−3.83, 6.48)    Ref       0.56 (−2.01, 3.14)     Ref
  **Amlodipine**                                                                                                                                                              
  Sample size                                    73,853                  73,853       35,004                  35,004   461,045               461,045   116,521                116,521
  Total person-years                             46,443                  47,776       35,451                  41,324   328,747               306,866   133,303                134,765
  *n* composite cardiovascular endpoint events   925                     939          601                     668      6,531                 6,125     2,370                  2,616
  Incidence rate/1,000 py                        19.92                   19.65        16.95                   16.17    19.87                 19.96     17.78                  19.41
  Incidence rate difference (95% CI)             0.26 (−1.53, 2.06)      Ref          0.79 (−1.04, 2.62)      Ref      −0.09 (−0.79, 0.60)   Ref       −1.63 (−2.66, −0.60)   Ref
  **Amlodipine-benazepril**                                                                                                                                                   
  Sample size                                    10,941                  10,941       6,034                   6,034    47,375                47,375    29,652                 29,652
  Total person-years                             5,866                   8,213        4,446                   5,790    25,821                42,414    24,656                 34,162
  *n* composite cardiovascular endpoint events   104                     99           49                      50       316                   427       263                    398
  Incidence rate/1,000 py                        17.73                   12.05        11.02                   8.64     12.24                 10.07     10.67                  11.65
  Incidence rate difference (95% CI)             5.67 (1.52, 9.83)       Ref          2.39 (−1.52, 6.29)      Ref      2.17 (0.52, 3.82)     Ref       −0.98 (−2.71, 0.74)    Ref
  **Calcitonin salmon**                                                                                                                                                       
  Sample size                                    1,054                   1,054        458                     458      7,420                 7,420     2,892                  2,892
  Total person-years                             251                     303          223                     237      1,737                 2,300     1,335                  1,511
  *n* fracture events                            16                      15           4                       2        129                   116       43                     41
  Incidence rate/1,000 py                        63.71                   49.46        17.92                   8.44     74.26                 50.44     32.22                  27.13
  Incidence rate difference (95% CI)             14.25 (−25.76, 54.27)   Ref          9.48 (−11.62, 30.58)    Ref      23.82 (8.06, 39.59)   Ref       5.09 (−7.62, 17.81)    Ref
  **Escitalopram**                                                                                                                                                            
  Sample size                                    24,445                  24,445       12,693                  12,693   127,803               127,803   134,298                134,298
  Total person-years                             6,492                   7,698        6,187                   6,453    39,229                57,741    60,221                 107,489
  *n* psychiatric hospitalizations               323                     356          85                      100      1,429                 1,766     595                    936
  Incidence rate/1,000 py                        49.75                   46.25        13.74                   15.50    36.43                 30.58     9.88                   8.71
  Incidence rate difference (95% CI)             3.50 (−3.74, 10.75)     Ref          −1.76 (−5.97, 2.46)     Ref      5.84 (3.48, 8.21)     Ref       1.17 (0.20, 2.14)      Ref
  **Glipizide**                                                                                                                                                               
  Sample size                                    2,193                   2,193        723                     723      66,713                66,713                           
  Total person-years                             1,745                   1,719        553                     576      44,940                42,077    2,470                  2,473
  *n* insulin initiations                        122                     94           34                      29       3,869                 3,088     159                    119
  Incidence rate/1,000 py                        69.92                   54.70        61.44                   50.36    86.09                 73.39     64.40                  48.10
  Incidence rate difference (95% CI)             15.23 (−1.39, 31.85)    Ref          11.08 (−16.53, 38.69)   Ref      12.70 (8.95, 16.45)   Ref       16.30 (3.00, 29.50)    Ref
  **Quinapril**                                                                                                                                                               
  Sample size                                    8,335                   8,335        14,369                  14,369   32,074                32,074    25,766                 25,766
  Total person-years                             5,476                   4,352        14,797                  11,893   22,580                19,778    35,060                 22,057
  *n* composite cardiovascular endpoint events   121                     121          286                     216      491                   389       582                    356
  Incidence rate/1,000 py                        22.10                   27.80        19.33                   18.16    21.74                 19.67     16.60                  16.14
  Incidence rate difference (95% CI)             −5.70 (−12.03, 0.62)    Ref          1.17 (−2.13, 4.46)      Ref      2.08 (−0.67, 4.82)    Ref       0.46 (−1.69, 2.61)     Ref
  **Sertraline**                                                                                                                                                              
  Sample size                                    177,959                 177,959      48,019                  48,019   639,272               639,272   107,150                107,150
  Total person-years                             71,333                  77,623       32,544                  33,825   260,109               314,073   72,249                 88,924
  *n* psychiatric hospitalizations               2,554                   2,546        308                     274      8,437                 8,637     576                    624
  Incidence rate/1,000 py                        35.80                   32.80        9.46                    8.10     32.44                 27.50     7.97                   7.02
  Incidence rate difference (95% CI)             3.00 (1.12, 4.89)       Ref          1.36 (−0.06, 2.79)      Ref      4.94 (4.03, 5.84)     Ref       0.96 (0.10, 1.81)      Ref

CI, confidence interval; py, person-years.

[S1 Fig](#pmed.1002763.s002){ref-type="supplementary-material"} summarizes treatment effect estimates for each comparison before PS matching, and [Fig 2](#pmed.1002763.g002){ref-type="fig"} summarizes treatment effect estimates for each comparison after PS matching. After pooling the PS-matched results from the 2 databases, a majority of the estimates indicated no differences in the rates of outcomes between the AG and generic versions of drugs. Of the 4 estimates that reached statistical significance, 3 suggested better outcomes among users of generic versus AG products (HR \[95% CI\] for patients switching from brand-name glipizide to AG versus generic: 1.32 \[1.07--1.64\]; for glipizide AG versus generic initiators: 1.19 \[1.14--1.25\]; for sertraline AG versus generic initiators: 1.06 \[1.04--1.09\]). By contrast, the comparison of patients switching from brand-name amlodipine to generic versus AG favored the AG (HR \[95% CI\]: 0.92 \[0.88--0.97\]).

![Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing outcomes for patients initiating authorized generics (AGs) versus generics, and patients switching from brand-name products to AGs versus generics, after 1:1 propensity score matching in each database.\
The outcome for amlodipine tablets, amlodipine-benazepril capsules, and quinapril tablets was a composite endpoint comprising hospitalization for myocardial infarction, ischemic stroke, or coronary revascularization procedures. The outcome for alendronate tablets and calcitonin salmon nasal spray was a composite non-vertebral fracture endpoint comprising humerus, wrist, hip, or pelvis fractures. The outcome for escitalopram tablets and sertraline tablets was hospitalization with a psychiatric condition as the principal discharge diagnosis code. The outcome for glipizide extended release (ER) tablets was initiation of insulin during the follow-up period.](pmed.1002763.g002){#pmed.1002763.g002}

Evaluation of comparative outcomes between generic and brand-name users {#sec019}
-----------------------------------------------------------------------

Across the 8 drug products and 2 databases, a total of 875,304 1:1 PS-matched pairs were included in the comparison of generic and brand-name initiators, and 437,857 1:1 PS-matched pairs were included in the comparison of AG and brand-name initiators. [Table 3](#pmed.1002763.t003){ref-type="table"} summarizes the patient demographics and baseline diagnoses for primary indications for all matched pairs for each drug product. Distributions of baseline characteristics were similar for generic, AG, and brand-name initiators after 1:1 PS pair matching, for each drug product within each database (See Tables R--Y in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"} for distribution before PS matching and Tables Z--AG in [S1 Appendix](#pmed.1002763.s001){ref-type="supplementary-material"} for distribution after PS matching). [Table 4](#pmed.1002763.t004){ref-type="table"} provides incidence rates for individual outcomes for patients included in this analysis.

10.1371/journal.pmed.1002763.t003

###### Characteristics of patients included in the evaluation of comparative outcomes for generic or authorized generic (AG) versus brand initiators after 1:1 propensity score matching in each database.

![](pmed.1002763.t003){#pmed.1002763.t003g}

  Characteristic               Optum            MarketScan                                                                                            
  ---------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Alendronate**                                                                                                                                     
  Number of patients           26,421           26,421           2,428            2,428            112,820          112,820          11,958           11,958
  Age: mean (SD)               59 (10)          59 (10)          60 (10)          60 (10)          64.01 (12)       64.25 (12)       63.48 (12)       63.22 (12)
  Male sex: *n* (%)            2,525 (9.6%)     2,535 (9.6%)     217 (8.9%)       223 (9.2%)       12,369 (11.0%)   12,545 (11.1%)   1,234 (10.3%)    1,253 (10.5%)
  Osteoporosis: *n* (%)        10,342 (39.1%)   10,229 (38.7%)   972 (40.0%)      951 (39.2%)      30,753 (27.3%)   30,929 (27.4%)   3,465 (29.0%)    3,417 (28.6%)
  **Amlodipine**                                                                                                                                      
  Number of patients           69,478           69,478           25,259           25,259           32,740           32,740           32,740           32,740
  Age: mean (SD)               54 (13)          54 (13)          56 (13)          56 (12)          60.60 (15)       60.64 (15)       60.37 (15)       60.64 (15)
  Male sex: *n* (%)            36,359 (52.3%)   36,178 (52.1%)   13,732 (54.4%)   13,754 (54.5%)   14,510 (44.3%)   14,896 (45.5%)   14,816 (45.3%)   14,896 (45.5%)
  Hypertension: *n* (%)        51,437 (74.0%)   51,891 (74.7%)   19,303 (76.4%)   19,223 (76.1%)   19,678 (60.1%)   19,530 (59.7%)   19,477 (59.5%)   19,530 (59.7%)
  **Amlodipine-benazepril**                                                                                                                           
  Number of patients           14,704           14,704           5,992            5,992            53,495           53,495           23,158           23,158
  Age: mean (SD)               52 (12)          52 (11)          54 (12)          53 (11)          54.65 (13)       54.65 (13)       54.88 (12)       54.65 (13)
  Male sex: *n* (%)            8,670 (59.0%)    8,758 (59.6%)    3,408 (56.9%)    3,491 (58.3%)    29,835 (55.8%)   30,014 (56.1%)   12,988 (56.1%)   13,250 (57.2%)
  Hypertension: *n* (%)        10,543 (71.7%)   10,453 (71.1%)   4,280 (71.4%)    4,131 (68.9%)    31,951 (59.7%)   31,660 (59.2%)   13,840 (59.8%)   13,584 (58.7%)
  **Calcitonin salmon**                                                                                                                               
  Number of patients           944              944              636              636              6,306            6,306            3,422            3,422
  Age: mean (SD)               62 (12)          62 (12)          59 (13)          60 (13)          68.37 (14)       68.42 (14)       66.23 (15)       65.77 (15)
  Male sex: *n* (%)            142 (15.0%)      145 (15.4%)      102 (16.0%)      96 (15.1%)       848 (13.4%)      847 (13.4%)      518 (15.1%)      537 (15.7%)
  Osteoporosis: *n* (%)        437 (46.3%)      440 (46.6%)      272 (42.8%)      262 (41.2%)      2,227 (35.3%)    2,165 (34.3%)    1,189 (34.7%)    1,196 (35.0%)
  **Escitalopram**                                                                                                                                    
  Number of patients           53,711           53,711           25,540           25,540           297,843          297,843          103,016          103,016
  Age: mean (SD)               39 (15)          39 (15)          39 (15)          39 (15)          42.58 (17)       42.46 (17)       42.61 (18)       42.20 (17)
  Male sex: *n* (%)            17,870 (33.3%)   17,982 (33.5%)   8,790 (34.4%)    8,725 (34.2%)    94,821 (31.8%)   94,674 (31.8%)   32,963 (32.0%)   32,891 (31.9%)
  Depression: *n* (%)          5,349 (10.0%)    5,160 (9.6%)     2,593 (10.2%)    2,556 (10.0%)    31,146 (10.5%)   30,921 (10.4%)   10,401 (10.1%)   9,875 (9.6%)
  Anxiety: *n* (%)             5,657 (10.5%)    5,383 (10.0%)    2,666 (10.4%)    2,436 (9.5%)     26,017 (8.7%)    26,425 (8.9%)    8,883 (8.6%)     8,420 (8.2%)
  **Glipizide**                                                                                                                                       
  Number of patients           997              997              825              825              2,388            2,388            2,246            2,246
  Age: mean (SD)               58 (13)          58 (13)          58 (11)          58 (12)          60.98 (14)       61.67 (13)       61.66 (13)       61.79 (13)
  Male sex: *n* (%)            539 (54.1%)      506 (50.8%)      452 (54.8%)      440 (53.3%)      1,223 (51.2%)    1,203 (50.4%)    1,124 (50.0%)    1,134 (50.5%)
  Diabetes mellitus: *n* (%)   695 (69.7%)      722 (72.4%)      596 (72.2%)      605 (73.3%)      1,539 (64.4%)    1,546 (64.7%)    1,488 (66.3%)    1,495 (66.6%)
  **Quinapril**                                                                                                                                       
  Number of patients           4,480            4,480            3,684            3,684            8,049            8,049            9,262            9,262
  Age: mean (SD)               53 (12)          53 (13)          54 (12)          54 (12)          56.58 (14)       56.55 (14)       58.48 (14)       58.47 (14)
  Male sex: *n* (%)            2,579 (57.6%)    2,599 (58.0%)    2,121 (57.6%)    2,138 (58.0%)    4,163 (51.7%)    4,189 (52.0%)    5,006 (54.0%)    5,039 (54.4%)
  Hypertension: *n* (%)        2,694 (60.1%)    2,653 (59.2%)    2,256 (61.2%)    2,242 (60.9%)    3,577 (44.4%)    3,481 (43.2%)    4,218 (45.5%)    4,160 (44.9%)
  **Sertraline**                                                                                                                                      
  Number of patients           54,493           54,493           55,674           55,674           132,986          132,986          132,056          132,056
  Age: mean (SD)               40 (15)          39 (15)          39 (15)          38 (15)          43.82 (18)       43.71 (18)       42.45 (17)       42.43 (18)
  Male sex: *n* (%)            17,110 (31.4%)   16,884 (31.0%)   17,472 (31.4%)   17,303 (31.1%)   41,625 (31.3%)   41,141 (30.9%)   41,584 (31.5%)   41,392 (31.3%)
  Depression: *n* (%)          4,985 (9.1%)     4,685 (8.6%)     5,278 (9.5%)     4,887 (8.8%)     9,312 (7.0%)     8,656 (6.5%)     9,919 (7.5%)     9,364 (7.1%)
  Anxiety: *n* (%)             4,025 (7.4%)     3,833 (7.0%)     4,323 (7.8%)     3,896 (7.0%)     6,101 (4.6%)     5,761 (4.3%)     6,660 (5.0%)     6,160 (4.7%)

10.1371/journal.pmed.1002763.t004

###### Outcome incidence rates for generic or authorized generic (AG) versus brand initiators after 1:1 propensity score matching in each database.

![](pmed.1002763.t004){#pmed.1002763.t004g}

  Characteristic                                 Optum                    MarketScan                                                                                                
  ---------------------------------------------- ------------------------ ------------ ------------------------ -------- ----------------------- --------- ------------------------ ---------
  **Alendronate**                                                                                                                                                                   
  Sample size                                    26,421                   26,421       2,428                    2,428    112,820                 112,820   11,958                   11,958
  Total person-years                             17,641                   11,832       627                      1,063    84,427                  62,862    3,518                    8,417
  *n* fracture events                            189                      148          11                       20       1,094                   951       55                       134
  Incidence rate/1,000 py                        10.71                    12.51        17.53                    18.81    12.96                   15.13     15.63                    15.92
  Incidence rate difference (95% CI)             −1.79 (−4.32, 0.73)      Ref          −1.28 (−14.52, 11.96)    Ref      −2.17 (−3.40, −0.94)    Ref       −0.29 (−5.22, 4.65)      Ref
  **Amlodipine**                                                                                                                                                                    
  Sample size                                    69,478                   69,478       25,259                   25,259   32,740                  32,740    32,740                   32,740
  Total person-years                             51,871                   31,604       18,331                   11,762   22,040                  9,560     23,720                   9,565
  *n* composite cardiovascular endpoint events   1,163                    1,001        420                      357      506                     310       530                      310
  Incidence rate/1,000 py                        22.42                    31.67        22.91                    30.35    22.96                   32.43     22.34                    32.41
  Incidence rate difference (95% CI)             −9.25 (−11.60, −6.90)    Ref          −7.44 (−11.28, −3.60)    Ref      −9.47 (−13.59, −5.34)   Ref       −10.07 (−14.14, −5.99)   Ref
  **Amlodipine-benazepril**                                                                                                                                                         
  Sample size                                    14,704                   14,704       5,992                    5,992    53,495                  53,495    23,158                   23,158
  Total person-years                             11,735                   8,074        3,963                    3,168    48,520                  35,431    15,222                   15,385
  *n* composite cardiovascular endpoint events   144                      140          63                       55       517                     486       180                      208
  Incidence rate/1,000 py                        12.27                    17.34        15.90                    17.36    10.66                   13.72     11.83                    13.52
  Incidence rate difference (95% CI)             −5.07 (−8.57, −1.57)     Ref          −1.46 (−7.50, 4.58)      Ref      −3.06 (−4.59, −1.53)    Ref       −1.69 (−4.22, 0.83)      Ref
  **Calcitonin salmon**                                                                                                                                                             
  Sample size                                    944                      944          636                      636      6,306                   6,306     3,422                    3,422
  Total person-years                             308                      307          177                      183      2,159                   2,336     907                      1,191
  *n* fracture events                            17                       16           8                        10       105                     101       56                       57
  Incidence rate/1,000 py                        55.21                    52.08        45.18                    54.74    48.64                   43.23     61.74                    47.86
  Incidence rate difference (95% CI)             3.12 (−33.48, 39.73)     Ref          −9.56 (−55.72, 36.60)    Ref      5.41 (−7.15, 17.96)     Ref       13.89 (−6.51, 34.28)     Ref
  **Escitalopram**                                                                                                                                                                  
  Sample size                                    53,711                   53,711       25,540                   25,540   301,337                 301,337   103,010                  103,010
  Total person-years                             14,007                   19,281       6,821                    9,215    149,419                 126,038   31,309                   42,636
  *n* psych hosp events                          674                      834          343                      396      4,635                   4,126     1,178                    1,319
  Incidence rate/1,000 py                        48.12                    43.26        50.29                    42.97    31.02                   32.74     37.63                    30.94
  Incidence rate difference (95% CI)             4.86 (0.19, 9.54)        Ref          7.31 (0.51, 14.11)       Ref      −1.72 (−3.06, −0.38)    Ref       6.69 (3.97, 9.41)        Ref
  **Glipizide**                                                                                                                                                                     
  Sample size                                    997                      997          825                      825      2,334                   2,334     2,202                    2,202
  Total person-years                             601                      422          525                      360      1,474                   999       1,808                    950
  *n* insulin events                             29                       25           35                       18       84                      62        91                       58
  Incidence rate/1,000 py                        48.27                    59.30        66.62                    49.96    56.98                   62.07     50.33                    61.08
  Incidence rate difference (95% CI)             −11.03 (−40.17, 18.10)   Ref          16.65 (−15.28, 48.59)    Ref      −5.08 (−24.76, 14.59)   Ref       −10.75 (−29.57, 8.06)    Ref
  **Quinapril**                                                                                                                                                                     
  Sample size                                    4,480                    4,480        3,684                    3,684    8,049                   8,049     9,262                    9,262
  Total person-years                             2,113                    1,662        2,360                    1,424    4,003                   3,295     7,325                    3,855
  *n* composite cardiovascular endpoint events   73                       60           55                       52       99                      97        163                      118
  Incidence rate/1,000 py                        34.54                    36.10        23.31                    36.53    24.73                   29.44     22.25                    30.61
  Incidence rate difference (95% CI)             −1.56 (−13.65, 10.54)    Ref          −13.22 (−24.90, −1.54)   Ref      −4.71 (−12.32, 2.91)    Ref       −8.36 (−14.85, −1.86)    Ref
  **Sertraline**                                                                                                                                                                    
  Sample size                                    54,493                   54,493       55,674                   55,674   132,995                 132,995   132,067                  132,067
  Total person-years                             25,322                   20,168       23,435                   20,465   68,982                  55,602    61,082                   54,877
  *n* psych hosp events                          670                      569          739                      659      1,413                   1,245     1,521                    1,355
  Incidence rate/1,000 py                        26.46                    28.21        31.53                    32.20    20.48                   22.39     24.90                    24.69
  Incidence rate difference (95% CI)             −1.75 (−4.82, 1.31)      Ref          −0.67 (−4.02, 2.68)      Ref      −1.91 (−3.55, −0.27)    Ref       0.21 (−1.61, 2.02)       Ref

py, person-years.

[S2 Fig](#pmed.1002763.s003){ref-type="supplementary-material"} summarizes treatment effect estimates for each product before PS matching, and [Fig 3](#pmed.1002763.g003){ref-type="fig"} summarizes treatment effect estimates for each product after PS matching. After PS matching, the comparison between generic and brand-name initiators ([Fig 3](#pmed.1002763.g003){ref-type="fig"}) suggested lower rates of the composite cardiovascular endpoint with the generic version for amlodipine and amlodipine-benazepril (HR \[95% CI\]: 0.91 \[0.84--0.99\] and 0.84 \[0.76--0.94\], respectively). For escitalopram and sertraline, a higher rate of hospitalization with a psychiatric diagnosis was observed among patients initiating generic versions compared to those initiating brand-name versions (HR \[95% CI\]: 1.05 \[1.01--1.10\] and 1.07 \[1.01--1.14\], respectively). Results from the negative control analysis also showed a numerically higher rate of hospitalization with a psychiatric condition among AG initiators compared to brand-name initiators for escitalopram (HR \[95% CI\]: 1.06 \[0.98--1.13\]) and a statistically significantly higher rate for sertraline (HR \[95% CI\]: 1.11 \[1.05--1.18\]). For alendronate, calcitonin, glipizide, and quinapril, no differences were observed in the outcomes of interest between generic and brand-name initiators.

![Hazard ratios (HRs) and 95% confidence intervals (CIs) comparing outcomes for authorized generic (AG) versus brand initiators and generic versus brand initiators after 1:1 propensity score matching in each database.\
The outcome for amlodipine tablets, amlodipine-benazepril capsules, and quinapril tablets was a composite endpoint comprising hospitalizations for myocardial infarction, ischemic stroke, or coronary revascularization procedures. The outcome for alendronate tablets and calcitonin salmon nasal spray was a composite non-vertebral fracture endpoint comprising humerus, wrist, hip, or pelvis fractures. The outcome for escitalopram tablets and sertraline tablets was hospitalization with a psychiatric condition as the principal discharge diagnosis code. The outcome for glipizide extended release (ER) tablets was initiation of insulin during the follow-up period.](pmed.1002763.g003){#pmed.1002763.g003}

Discussion {#sec020}
==========

In this study conducted using 2 large US commercial insurance databases, we used AGs---generic versions of brand-name products that are chemically identical and identical in appearance to the branded product---to account for potential bias due to negative perceptions towards generics in comparing the effectiveness of brand-name versus generic products. We observed equivalent or better clinical outcomes among patients who used generic versus AG products in 15 out of 16 comparisons across 8 drug products. When directly comparing individuals who initiated treatment with generic versus brand-name products, we used AGs versus brand-name products as a negative control comparison. For the 2 drugs for which we observed higher rates of hospitalization with a psychiatric condition with the generic version compared to the brand-name version---escitalopram and sertraline---the negative control comparisons also tended towards higher rates with AG use compared to brand-name use, suggesting that the differences observed between brand-name and generic users in these outcomes were likely explained by residual confounding or generic perception bias.

Our results add to a growing body of literature supporting the clinical equivalence of brand-name products and FDA-approved bioequivalent generic versions \[[@pmed.1002763.ref002],[@pmed.1002763.ref003],[@pmed.1002763.ref017],[@pmed.1002763.ref028],[@pmed.1002763.ref029]\]. With 2 large national databases and a PS-matched design, we aimed to address the possibility of perception bias affecting comparative effectiveness estimates in observational studies of generic drugs by considering AGs as a control group. We found largely consistent results across 8 drug products and 4 therapeutic classes. In the comparison involving patients switching from amlodipine brand-name to AG or generic, in which we found a lower rate of the composite cardiovascular endpoint with AG use compared to generic use, the effect size was modest (HR of 0.92 with upper 95% confidence limit of 0.97) and should be interpreted cautiously given the multiple comparisons that were undertaken. We did not correct for multiple testing to control type I error because this would increase type II error and potentially result in a missed signal \[[@pmed.1002763.ref030]\]. Therefore, type I error might explain the statistically significant findings in the current study.

Although use of generic medications has increased rapidly in the past 2 decades, in recent national surveys about one-third of patients, physicians, and pharmacists were still classified as skeptics about the safety, effectiveness, and quality of generic medications \[[@pmed.1002763.ref009],[@pmed.1002763.ref011]\]. Negative perceptions may lead patients to switch back to the brand-name product after generic substitution. Indeed, switching back to the brand-name product after a brand-name to generic switch is highly prevalent. In a previous study of the 8 drug products included in this study, we found that switching back to the brand-name product occurred at a rate of 8.9 per 100 person-years after a switch to a generic version, and a rate of 7.4 per 100 person-years after a switch to AG \[[@pmed.1002763.ref031]\]. Switching back to the brand-name product when less expensive generic alternatives are available can result in unnecessary costs to patients and the healthcare system. Use of low-cost generic alternatives in place of brand-name drugs saved the US approximately \$1 trillion over the last decade \[[@pmed.1002763.ref032]\]. Results from our comparative effectiveness investigation suggest that clinical outcomes with use of generics and brand products for serious chronic conditions such as diabetes, hypertension, osteoporosis, and depression and anxiety are broadly equivalent. These results may inform clinical practice by guiding the development of educational interventions to address physicians' and patients' negative perceptions of generics and to increase awareness regarding the equivalence of generic and brand-name drugs. For instance, results from the current and previous studies \[[@pmed.1002763.ref002],[@pmed.1002763.ref003],[@pmed.1002763.ref017],[@pmed.1002763.ref028],[@pmed.1002763.ref029]\] could be used to develop educational materials for clinical outreach initiatives such as academic detailing, where trained clinical educators including physicians, nurses, and pharmacists present concise summaries of the evidence demonstrating brand and generic equivalence to practitioners in their offices \[[@pmed.1002763.ref033]\]. Similar educational interventions targeted at patients delivered by trained pharmacy personnel could increase perseverance on generic medications and reduce the rate of patients switching back to the brand-name products.

The most important strength of this study is the use of AGs as a control exposure to indirectly account for perception biases that are not recorded in any data sources. Another major strength is inclusion of patients from 2 large data sources, which provided large sample sizes for most analyses. Further, rigorous confounding control was made possible by the availability of comprehensive longitudinal insurance claims data in both sources. Finally, inclusion of 8 different drugs from 4 therapeutic classes ensures generalizability of our results across multiple therapeutic classes.

However, our study also has several limitations. First, the data were sourced from 2 commercial health insurance databases from the US that do not collect information about clinical parameters such as cholesterol or bone mineral density, introducing the possibility of residual confounding. For instance, if the brand version of alendronate is preferentially used in patients with low bone mineral density due to a perception of higher effectiveness, then residual confounding by this factor could bias the results in favor of the generic version. We sought to address this limitation by including a large number of measured confounding variables in our PS models, many of which are likely to be correlated with unmeasured factors. Second, no narrow therapeutic index drugs---which have been the subject of particular concern regarding generic safety and effectiveness---met the criteria for inclusion in this study \[[@pmed.1002763.ref010]\]. Therefore our results may not generalize to these types of drugs, and future research comparing the effectiveness and safety of generic versus brand versions of narrow therapeutic index drugs is recommended. Third, we were not able to examine surrogate outcome measures, such as blood pressure changes or changes in lipid levels, as outcomes since the data sources do not contain this information. It is possible that slight differences in the bioavailability of different versions of the same drug could lead to small changes in laboratory values. Changes in laboratory results or other surrogate measures after switching to generics from brand-name drugs may be important to identify and characterize in future research. For instance, immediate changes in blood pressure control after switching from brand to generic amlodipine, perhaps due to the nocebo effect, could lead to compromised patient compliance. Therefore, products for which such changes are common should be identified and prioritized for patient counseling by pharmacists or physicians.

Conclusion {#sec021}
==========

In this study of 8 drug products conducted using 2 large US commercial insurance databases, we observed that use of generics provided comparable clinical outcomes as the brand products. These results could be used in educational interventions aimed at increasing patient and physician confidence in the ability of generic medicines to manage chronic diseases.
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AG

:   authorized generic

CI

:   confidence interval
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FDA

:   US Food and Drug Administration

HR

:   hazard ratio

NDC

:   National Drug Code

PS

:   propensity score
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